PASSAGE BIO INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
PASSAGE BIO INC. - More news...
PASSAGE BIO INC. - More news...
- Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights
- Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1
- Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020
- Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease
- Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis
- Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic
- Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa
- Passage Bio to Participate in Upcoming October Investor Conferences
- Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program
- Passage Bio to Participate in Citi’s 15th Annual BioPharma Virtual Conference
- Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights
- Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020
- Passage Bio Added to Russell 2000 Index
- Passage Bio to Present at Goldman Sachs 41st Annual Global Healthcare Conference
- Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis
- Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
- Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights
- Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania
- Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020
- FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis
- Passage Bio to Present at 19th Annual Needham Healthcare Conference
- Passage Bio to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day
